Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23654214 | 0.85 | — | — | |
| SCHEMBL16006486 | 0.84 | CRHR1 (0.39) | MAPTALDH1A1 | |
| SCHEMBL20430361 | 0.83 | — | — | |
| SCHEMBL19788772 | 0.83 | KCNA5 (0.31) | — | |
| SCHEMBL16006487 | 0.82 | LRRK2 (0.33) | — | |
| SCHEMBL17621605 | 0.81 | CHRM4 (0.31) | — | |
| SCHEMBL20429948 | 0.75 | — | — | |
| SCHEMBL16006821 | 0.73 | ALDH1A1 (0.50) | MAPTHTTALDH1A1 | |
| SCHEMBL24249583 | 0.73 | — | — | |
| SCHEMBL16006406 | 0.73 | CCR4 (0.36) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262990-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2014134566-A2 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | MAPT 1547/4885HTT 3665/4885ALDH1A1 351/4885 |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | MAPT 1618/4885HTT 3558/4885ALDH1A1 372/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | MAPT 1618/4885HTT 3558/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.